CliffBio
biologic

Opdivo

nivolumab

Loss of exclusivityAugust 2033projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →View the full company profile on CliffBio

Drug detail

Brand nameOpdivo
Active ingredientnivolumab
Strength120MG/12ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2021
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Opdivo patent cliff — loss of exclusivity August 2033 | CliffBio